University Hospital of Lyon, 59 boulevard Pinel, Lyon, France.
Neuroimage. 2012 Jun;61(2):363-70. doi: 10.1016/j.neuroimage.2011.12.037. Epub 2011 Dec 28.
Neuroimaging of brain receptors began in the early 1980s. Now, some thirty-five years later, PET imaging is still an expanding field of preclinical and clinical investigations. In addition to improvements in PET cameras and image analysis, the availability of suitable radiotracers is a crucial factor leading this expansion. Radiotracers have been developed to visualize and quantify a growing numbers of brain receptors, transporters, enzymes and other molecular targets. The development of adequate PET radiotracers represents an exciting challenge, given the large number of targets and neurochemical functions that have yet to be explored. In this article, we review the main evolutions led by preclinical radiotracers and clinical radiopharmaceuticals. The current main contributions of PET radiotracers are described in terms of imaging of neuronal metabolism, receptor and transporter quantification and neurodegenerative, neuroinflammatory and neurooncologic process imaging. In the last part, we highlight some applications presenting a potential for novel functional explorations of the brain.
脑受体的神经影像学研究始于 20 世纪 80 年代早期。如今,三十五年过去了,正电子发射断层扫描(PET)成像仍然是一个不断发展的临床前和临床研究领域。除了 PET 相机和图像分析的改进外,合适的放射性示踪剂的可用性是推动这一领域发展的关键因素。放射性示踪剂已被开发用于可视化和定量越来越多的脑受体、转运体、酶和其他分子靶点。鉴于仍有大量的靶点和神经化学功能有待探索,开发足够的正电子发射断层扫描放射性示踪剂是一个令人兴奋的挑战。在本文中,我们回顾了临床前放射性示踪剂和临床放射性药物带来的主要进展。根据神经元代谢、受体和转运体定量以及神经退行性、神经炎症和神经肿瘤过程成像,描述了正电子发射断层扫描放射性示踪剂的当前主要贡献。在最后一部分,我们强调了一些具有探索大脑新功能潜力的应用。